STAT

OCTOBER 22, 2024

Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex for the pharmacies to safely make. The FDA still has to make a decision on whether to officially place semaglutide on the lists.

Compounding 362

Compounding Compounding Pharmacies Documentation Diabetes 362

STAT

OCTOBER 23, 2024

Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex for the pharmacies to safely make , STAT reports. … Novo Nordisk has asked the U.S.

Compounding 265

Compounding Compounding Pharmacies Biosimilars Documentation 265

STAT

DECEMBER 4, 2024

It mirrors results seen in the companies’ diabetes drugs, which use the same active ingredients. But documenting the differences between Zepbound and Wegovy in a rigorous way might allow Lilly to make marketing claims about Zepbound’s superior efficacy. That, in turn, could help the company gain market share against Novo. 

Compounding 233

Compounding Compounding Pharmacies Diabetes Documentation 233